8-K - KORU Medical Systems, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

KORU Medical Systems reported Q4 and FY 2025 financial results with full year revenue growth of 22% to $41.1 million and a 57% improvement in net loss. The company initiated FY 2026 guidance projecting revenue of $47.5 - $50.0 million and positive adjusted EBITDA.

Key Takeaways

1Full year 2025 net revenues grew 22% to $41.1 million, with International Core revenue increasing 80%.

2Full year 2025 net loss improved 57% to ($2.6) million, or ($0.06) per diluted share.

3Full year 2025 Adjusted EBITDA was positive $0.6 million, compared to ($2.5) million in the prior year.

4The company initiated FY 2026 guidance for net revenues of $47.5 - $50.0 million (15% - 22% growth) and positive adjusted EBITDA.

5Ending cash balance was $8.9 million as of December 31, 2025, with annual cash usage of $0.7 million.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

of the Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise sub

Financial Results

9.01

. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated March 12, 2026 104 Cover Page Interactive Data File (embed

Exhibits Only

Source Document

Results of Operations

Fourth Quarter Fiscal 2025

Metric	Value	Basis	Prior Period
Revenue	$10.90		$8.84
Gross Profit	$6.80		$5.50
Gross Margin	62.6%		62.9%
Net Loss	$-0.50	GAAP	$-1.60
Diluted EPS	$-0.01	GAAP	$-0.03
Adjusted EBITDA	$0.50	Non-GAAP	$-0.70

Forward Guidance

Full Year 2026

Revenue

47.5 - 50.0

Gross Margin

61 - 63

Adjusted EBITDA

—

Non-GAAP

Cash Flow

—

Exhibits (2)

8-K

FORM 8-K CURRENT REPORT FOR 03-12-2026

PRESS RELEASE, DATED MARCH 12, 2026